Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 28, 2014; 20(32): 11400-11405
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11400
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11400
Table 3 Summary of the improvement in the urine excretion, ascites and edema after tolvaptan treatment, according to grading criteria, and in the overall improvement n (%)
n | Significant improvement | Improvement | No improvement | |
Urine excretion | 39 | 26 (66.7) | 9 (23.1) | 4 (10.3) |
Abdominal circumference | 39 | 19 (48.7) | 13 (33.3) | 7 (17.9) |
Edema (lower extremities) | 24 | 17 (70.8) | 5 (20.8) | 2 (8.3) |
Overall improvement for all patients1 | 39 | 18 (46.2) | 17 (43.6) | 4 (10.2) |
Overall improvement in patients with coexisting hepatocellular carcinoma1 | 19 | 9 (47.4) | 7 (36.8) | 3 (15.8) |
Overall improvement in patients with coexisting hepatorenal syndrome (Type 1)1 | 2 | 0 (0) | 0 (0) | 2 (100.0) |
Overall improvement in patients with coexisting hepatorenal syndrome (Type 2)1 | 7 | 2 (28.6) | 5 (71.4) | 0 (0) |
- Citation: Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405
- URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11400